

ABSTRACT**BIOMARKERS FOR PREDICTING IMMUNOGENICITY AND THERAPEUTIC
RESPONSES TO ADALIMUMAB IN RHEUMATOID ARTHRITIS PATIENTS**

- 5 A method for predicting an immunogenic and/or therapeutic response to adalimumab from a sample extracted from a rheumatoid arthritis patient by testing the sample for the presence of biomarkers, the biomarkers being autoantibodies to antigens comprising SSB, TROVE2 and ZHX2.
- 10 (Figure 6)